

# Udaya S Tantry

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6483438/udaya-s-tantry-publications-by-year.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

239  
papers

13,428  
citations

54  
h-index

112  
g-index

302  
ext. papers

15,282  
ext. citations

5.7  
avg, IF

6.21  
L-index

#	Paper	IF	Citations
239	Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium.. <i>Nature Reviews Cardiology</i> , <b>2022</b> ,	14.8	16
238	Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes.. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2022</b> , 53, 363	5.1	3
237	Pharmacosimulation of delays and interruptions during administration of tirofiban: a systematic comparison between EU and US dosage regimens.. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2022</b> , 1	5.1	
236	Measurement of Anticoagulation in Patients on Dabigatran, Rivaroxaban, and Apixaban Therapy by Novel Automated Thrombelastography.. <i>TH Open</i> , <b>2021</b> , 5, e570-e576	2.7	0
235	Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction. <i>JACC Basic To Translational Science</i> , <b>2021</b> , 6, 749-761	8.7	0
234	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , <b>2021</b> ,	1.4	1
233	Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 902-904	5.1	8
232	First Experience Addressing the Prognostic Utility of Novel Urinary Biomarkers in Patients With COVID-19. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, ofab274	1	5
231	International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 992-998	5.1	3
230	Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y antagonists. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 52, 272-280	5.1	
229	Platelet Reactivity and Coagulation Markers in Patients with COVID-19. <i>Advances in Therapy</i> , <b>2021</b> , 38, 3911-3923	4.1	10
228	Effects of Monotherapy with Clopidogrel vs. Aspirin on Vascular Function and Hemostatic Measurements in Patients with Coronary Artery Disease: The Prospective, Crossover I-LOVE-MONO Trial. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	1
227	An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , <b>2021</b> , 26, 40-50	2.6	1
226	Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B and agonist-induced platelet aggregation. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 260-264	5.1	4
225	The East Asian Paradox: An Updated Position Statement on the Challenges to the Current Antithrombotic Strategy in Patients with Cardiovascular Disease. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 422-432	7	47
224	Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2021</b> , 51, 454-465	5.1	6
223	Ethnic Difference of Thrombogenicity in Patients with Cardiovascular Disease: a Pandora Box to Explain Prognostic Differences. <i>Korean Circulation Journal</i> , <b>2021</b> , 51, 202-221	2.2	5

222	Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 1376-1386	7	6
221	Thrombogenicity markers for early diagnosis and prognosis in COVID-19: a change from the current paradigm?. <i>Blood Coagulation and Fibrinolysis</i> , <b>2021</b> , 32, 544-549	1	4
220	The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. <i>Platelets</i> , <b>2021</b> , 1-11	3.6	1
219	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent.. <i>Journal of Experimental Pharmacology</i> , <b>2021</b> , 13, 957-970	3	0
218	Race-Related disparities in COVID-19 thrombotic outcomes: Beyond social and economic explanations. <i>EClinicalMedicine</i> , <b>2020</b> , 29, 100647	11.3	9
217	Vorapaxar in the treatment of cardiovascular diseases. <i>Future Cardiology</i> , <b>2020</b> , 16, 373-384	1.3	4
216	Antithrombotic treatment strategies after PCI. <i>Lancet, The</i> , <b>2020</b> , 395, 866-867	40	
215	Synergistic influence of rivaroxaban on inflammation and coagulation biomarkers in patients with coronary artery disease and peripheral artery disease on aspirin therapy. <i>Future Cardiology</i> , <b>2020</b> , 16, 69-75	1.3	1
214	Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 484-498	5.1	3
213	Effect of Smoking Cessation on the Pharmacokinetics and Pharmacodynamics of Clopidogrel after PCI: The Smoking Cessation Paradox Study. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 449-456	7	5
212	Assessing platelet reactivity after drug eluting stent implantation: state of the art. <i>Expert Review of Cardiovascular Therapy</i> , <b>2020</b> , 18, 17-24	2.5	
211	The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 50, 969-981	5.1	4
210	Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. <i>Progress in Cardiovascular Diseases</i> , <b>2020</b> , 63, 243-248	8.5	2
209	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , <b>2020</b> , 27, 661-676	1.4	4
208	Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. <i>Anesthesiology</i> , <b>2020</b> , 133, 1263-1276	4.3	5
207	Investigational drugs in phase II clinical trials for acute coronary syndromes. <i>Expert Opinion on Investigational Drugs</i> , <b>2020</b> , 29, 33-47	5.9	5
206	First In-Human Experience With Inhaled Acetylsalicylic Acid for Immediate Platelet Inhibition: Comparison With Chewed and Swallowed Acetylsalicylic Acid. <i>Circulation</i> , <b>2020</b> , 142, 1305-1307	16.7	4
205	Meta-Analysis of the Usefulness of Therapeutic Hypothermia After Cardiac Arrest. <i>American Journal of Cardiology</i> , <b>2020</b> , 133, 48-53	3	5

204	Targeted pharmacotherapy for ischemia reperfusion injury in acute myocardial infarction. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 1851-1865	4	14
203	Personalizing Antithrombotic Therapy in COVID-19: Role of Thromboelastography and Thromboelastometry. <i>Thrombosis and Haemostasis</i> , <b>2020</b> , 120, 1594-1596	7	18
202	Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates. <i>Nature Biomedical Engineering</i> , <b>2020</b> , 4, 1188-1196	19	40
201	Direct oral anticoagulants: a review on the current role and scope of reversal agents. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 271-286	5.1	30
200	Effects of vorapaxar on clot characteristics, coagulation, inflammation, and platelet and endothelial function in patients treated with mono- and dual-antiplatelet therapy. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 23-35	15.4	8
199	"Blueprinting" thrombogenicity and antithrombotic drug response at the bedside in patients presenting emergently with symptoms of acute stroke. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 192-199	5.1	10
198	Gender differences in thrombogenicity among patients with angina and non-obstructive coronary artery disease. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 48, 373-381	5.1	8
197	Combination Antiplatelet and Oral Anticoagulant Therapy in Patients With Coronary and Peripheral Artery Disease. <i>Circulation</i> , <b>2019</b> , 139, 2170-2185	16.7	49
196	Secondary prevention of ischaemic stroke: more evidence to block two pathways affecting platelet activation. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , <b>2019</b> , 5, 275-278	4.6	1
195	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , <b>2019</b> , 12, 1521-1537	5	189
194	Smoking and cardiovascular diseases: paradox greater than expected?. <i>Polish Archives of Internal Medicine</i> , <b>2019</b> , 129, 700-706	1.9	4
193	In search for an optimal antithrombotic regimen in patients with atrial fibrillation undergoing stenting. <i>Kardiologia Polska</i> , <b>2019</b> , 77, 817-819	0.9	
192	2018 update of expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. <i>Science Bulletin</i> , <b>2019</b> , 64, 166-179	10.6	17
191	A narrative review of the cardiovascular risks associated with concomitant aspirin and NSAID use. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2019</b> , 47, 16-30	5.1	10
190	HDL-C is a Marker of Coronary Artery Disease Severity and Inflammation in Patients on Statin Therapy. <i>Cardiovascular Revascularization Medicine</i> , <b>2019</b> , 20, 1001-1006	1.6	2
189	Influence of Amlodipine on Haemostatic Measurements during Clopidogrel Treatment in Patients with Coronary Artery Disease. <i>Thrombosis and Haemostasis</i> , <b>2019</b> , 119, 264-273	7	2
188	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2018</b> , 319, 1566-1579	27.4	205
187	Combination oral antithrombotic therapy for the treatment of myocardial infarction: recent developments. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 653-665	4	13

186	Selection of P2Y Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome. <i>Progress in Cardiovascular Diseases</i> , <b>2018</b> , 60, 460-470	8.5	7
185	Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 469-476 <sup>5.1</sup>	5.1	9
184	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. <i>International Journal of Cardiology</i> , <b>2018</b> , 269, 292-297	3.2	10
183	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , <b>2018</b> , 16, 419-429	2.5	4
182	Cangrelor for the treatment of patients with Arterial Thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 1389-1398	4	3
181	Peri-Procedural Platelet Reactivity in Percutaneous Coronary Intervention. <i>Thrombosis and Haemostasis</i> , <b>2018</b> , 118, 1131-1140	7	6
180	Should Antithrombotic Treatment Strategies in East Asians Differ from Caucasians?. <i>Current Vascular Pharmacology</i> , <b>2018</b> , 16, 459-476	3.3	20
179	Thrombogenicity and central pulse pressure to enhance prediction of ischemic event occurrence in patients with established coronary artery disease: The MAGMA-ischemia score. <i>Atherosclerosis</i> , <b>2018</b> , 268, 55-62	3.1	3
178	Thromboxane inhibition during concurrent therapy with low-dose aspirin and over-the-counter naproxen sodium. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2018</b> , 45, 18-26	5.1	3
177	Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy?. <i>Circulation</i> , <b>2018</b> , 138, 2145-2159	16.7	23
176	The potential of genotype-guided antiplatelet therapy: promises and challenges. <i>Expert Review of Precision Medicine and Drug Development</i> , <b>2018</b> , 3, 371-377	1.6	
175	Antithrombotic Strategies and Device Thrombosis. <i>Cardiology Clinics</i> , <b>2018</b> , 36, 541-550	2.5	6
174	Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a new-generation thrombelastography TEG 6s system. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 43, 437-445	5.1	44
173	Bleeding and thrombosis associated with ventricular assist device therapy. <i>Journal of Heart and Lung Transplantation</i> , <b>2017</b> , 36, 1164-1173	5.8	57
172	GEMINI-ACS-1: toward unearthing the antithrombotic therapy cornerstone for acute coronary syndromes. <i>Lancet, The</i> , <b>2017</b> , 389, 1773-1775	40	10
171	Efficacy of aspirin (325 mg) + omeprazole (40 mg) in treating coronary artery disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 123-131	4	5
170	International Expert Consensus on Switching Platelet P2Y Receptor-Inhibiting Therapies. <i>Circulation</i> , <b>2017</b> , 136, 1955-1975	16.7	215
169	Novel role of platelet reactivity in adverse left ventricular remodelling after ST-segment elevation myocardial infarction: The REMODELING Trial. <i>Thrombosis and Haemostasis</i> , <b>2017</b> , 117, 911-922	7	10

168	Low-density lipoprotein 4: a novel predictor of coronary artery disease severity. <i>Current Medical Research and Opinion</i> , <b>2017</b> , 33, 1979-1984	2.5	9
167	Central aortic pulse pressure, thrombogenicity and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2017</b> , 44, 223-233	5.1	3
166	Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. <i>Platelets</i> , <b>2017</b> , 28, 187-193	3.6	1
165	Oxidized Low-Density Lipoprotein- $\beta$ -Glycoprotein I Complex But Not Free Oxidized LDL Is Associated With the Presence and Severity of Coronary Artery Disease. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 673-8	3	9
164	Does Platelet Reactivity Predict Bleeding in Patients Needing Urgent Coronary Artery Bypass Grafting During Dual Antiplatelet Therapy?. <i>Annals of Thoracic Surgery</i> , <b>2016</b> , 102, 2010-2017	2.7	28
163	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. <i>Expert Review of Cardiovascular Therapy</i> , <b>2016</b> , 14, 1361-1370	2.5	3
162	Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review. <i>Annals of Internal Medicine</i> , <b>2016</b> , 164, 600-7	8	40
161	Coagulation Abnormalities in Heart Failure: Pathophysiology and Therapeutic Implications. <i>Current Heart Failure Reports</i> , <b>2016</b> , 13, 319-328	2.8	17
160	Thrombin-Induced Platelet-Fibrin Clot Strength Identified by Thrombelastography: A Novel Prothrombotic Marker of Coronary Artery Stent Restenosis. <i>Journal of Interventional Cardiology</i> , <b>2016</b> , 29, 168-78	1.8	12
159	Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events. <i>Expert Review of Cardiovascular Therapy</i> , <b>2016</b> , 14, 779-91	2.5	2
158	Association of weight gain with coronary artery disease, inflammation and thrombogenicity. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2016</b> , 41, 394-403	5.1	3
157	Cell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2016</b> , 36, 189-97	9.4	71
156	Drug delivery and therapeutic impact of extended-release acetylsalicylic acid. <i>Future Cardiology</i> , <b>2016</b> , 12, 45-58	1.3	10
155	To stop or continue aspirin before aortocoronary bypass operations-do we have enough evidence to adequately guide us?. <i>Journal of Thoracic Disease</i> , <b>2016</b> , 8, E578-80	2.6	
154	State of the art: Oral antiplatelet therapy. <i>JRSM Cardiovascular Disease</i> , <b>2016</b> , 5, 2048004016652514	1.1	5
153	Statin therapy and inflammation in patients with diabetes treated with high dose aspirin. <i>Journal of Diabetes and Its Complications</i> , <b>2016</b> , 30, 1365-70	3.2	5
152	Timing of Coronary Bypass Surgery in Patients Receiving Clopidogrel: The Role of VerifyNow. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 724-5	3.8	8
151	CardioPulse: Platelet inhibitors and their differences. <i>European Heart Journal</i> , <b>2016</b> , 37, 323-6	9.5	

150	Platelet-Mediated Thrombosis: From Bench to Bedside. <i>Circulation Research</i> , <b>2016</b> , 118, 1380-91	15.7	36
149	First report of the point-of-care TEG: A technical validation study of the TEG-6S system. <i>Platelets</i> , <b>2016</b> , 27, 642-649	3.6	101
148	Antiplatelet Effect Durability of a Novel, 24-Hour, Extended-Release Prescription Formulation of Acetylsalicylic Acid in Patients With Type 2 Diabetes Mellitus. <i>American Journal of Cardiology</i> , <b>2016</b> , 118, 1941-1947	3	12
147	Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis) Study. <i>Circulation</i> , <b>2016</b> , 133, 100-107	3.2	11
146	Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2015</b> , 36, 1762-71	9.5	218
145	Relation of fish oil supplementation to markers of atherothrombotic risk in patients with cardiovascular disease not receiving lipid-lowering therapy. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 1204-11	3	14
144	Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , <b>2015</b> , 163, 40-51	8	281
143	Platelet activation and pneumonia: is soluble p-selectin the right marker?. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 1492-3	15.1	3
142	P2Y12 receptor inhibitors for secondary prevention of ischemic stroke. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 1149-65	4	12
141	Meta-analysis of direct and indirect comparison of ticagrelor and prasugrel effects on platelet reactivity. <i>American Journal of Cardiology</i> , <b>2015</b> , 115, 716-23	3	27
140	Is light transmittance aggregometry still a useful tool to assess pharmacodynamic effects of antiplatelet therapy?. <i>Platelets</i> , <b>2015</b> , 26, 608-9	3.6	1
139	Vorapaxar in the secondary prevention of atherothrombosis. <i>Expert Review of Cardiovascular Therapy</i> , <b>2015</b> , 13, 1293-305	2.5	9
138	Current antiplatelet treatment strategy in patients with diabetes mellitus. <i>Diabetes and Metabolism Journal</i> , <b>2015</b> , 39, 95-113	5	20
137	G-protein-coupled receptors signaling pathways in new antiplatelet drug development. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2015</b> , 35, 500-12	9.4	53
136	Platelet Activation and Aggregation in Patients with Advanced Adenocarcinoma Undergoing Chemotherapy: Correlation with a Validated Venous Thromboembolism Risk Score. <i>Blood</i> , <b>2015</b> , 126, 3445-3445	2.2	2
135	Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. <i>JACC: Heart Failure</i> , <b>2014</b> , 2, 1-14	7.9	40
134	Light Transmission Aggregometry <b>2014</b> , 51-57		
133	Thrombelastography and Other Novel Techniques <b>2014</b> , 102-107		

132	Platelet reactivity during ticagrelor maintenance therapy: a patient-level data meta-analysis. <i>American Heart Journal</i> , <b>2014</b> , 168, 530-6	4.9	36
131	Platelet Pathophysiology and its Role in Thrombosis <b>2014</b> , 1-7		
130	Role of Inflammation and Hypercoagulability in Thrombosis <b>2014</b> , 45-50		2
129	Personalizing Antiplatelet Therapy <b>2014</b> , 267-276		
128	Clopidogrel Resistance <b>2014</b> , 285-292		1
127	Resistance to antiplatelet drugs: what progress has been made?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 2553-64	4	28
126	Pharmacodynamic efficacy and safety of adjunctive cilostazol loading to clopidogrel and aspirin loading: the results of the ACCEL-LOADING (Accelerated Platelet Inhibition by Cilostazol Loading) study. <i>International Journal of Cardiology</i> , <b>2014</b> , 174, 129-32	3.2	2
125	Update: Acute coronary syndromes (V). Personalized antiplatelet therapy. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2014</b> , 67, 480-7	0.7	1
124	The effect of CYP2C19 gene polymorphisms on the pharmacokinetics and pharmacodynamics of prasugrel 5-mg, prasugrel 10-mg and clopidogrel 75-mg in patients with coronary artery disease. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 589-97	7	23
123	PRASFIT-ACS: important evidence against a "one-guideline-fits-all-races" approach to antiplatelet therapy. <i>Circulation Journal</i> , <b>2014</b> , 78, 2563	2.9	1
122	Unravelling the smokersParadox: cigarette smoking, high-risk coronary artery disease and enhanced clinical efficacy of oral P2Y <sub>12</sub> inhibitors. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 1187-90	7	10
121	Thrombin-induced platelet-fibrin clot strength: relation to high on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 111, 713-24	7	16
120	Statin therapy and thromboxane generation in patients with coronary artery disease treated with high-dose aspirin. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 323-31	7	7
119	Effect of adjunctive dipyridamole to DAPT on platelet function profiles in stented patients with high platelet reactivity. The result of the ACCEL-DIP Study. <i>Thrombosis and Haemostasis</i> , <b>2014</b> , 112, 1198-208	7	6
118	Pharmacodynamic effects of cilostazol versus clopidogrel in stented patients under proton pump inhibitor co-administration: the ACCEL-PARAZOL study. <i>Journal of Atherosclerosis and Thrombosis</i> , <b>2014</b> , 21, 1121-39	4	3
117	Review of pharmacokinetic and pharmacodynamic modeling and safety of proton pump inhibitors and aspirin. <i>Expert Review of Clinical Pharmacology</i> , <b>2014</b> , 7, 645-53	3.8	4
116	Influence of race and sex on thrombogenicity in a large cohort of coronary artery disease patients. <i>Journal of the American Heart Association</i> , <b>2014</b> , 3, e001167	6	14
115	Letter by Grbel et al regarding article, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome". <i>Circulation: Cardiovascular Interventions</i> , <b>2014</b> , 7, 273	6	1

114	Cangrelor: an emerging therapeutic option for patients with coronary artery disease. <i>Current Medical Research and Opinion</i> , <b>2014</b> , 30, 813-28	2.5	24
113	Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , <b>2013</b> , 158, 261-70	8	115
112	Relation between the vasodilator-stimulated phosphoprotein phosphorylation assay and light transmittance aggregometry in East Asian patients after high-dose clopidogrel loading. <i>American Heart Journal</i> , <b>2013</b> , 166, 95-103	4.9	13
111	The Role of Platelet Function Testing in Risk Stratification and Clinical Decision-Making. <i>Interventional Cardiology Clinics</i> , <b>2013</b> , 2, 607-614	1.4	1
110	Spaced administration of PA32540 and clopidogrel results in greater platelet inhibition than synchronous administration of enteric-coated aspirin and enteric-coated omeprazole and clopidogrel. <i>American Heart Journal</i> , <b>2013</b> , 165, 176-82	4.9	6
109	Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 2261-73	15.1	693
108	Potential role of oral anticoagulants in the treatment of patients with coronary artery disease: focus on dabigatran. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 1259-67	2.5	5
107	Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 1029-49	2.5	4
106	Importance of measurement of platelet reactivity to ADP in patients with coronary artery disease: an historical account. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 1547-56	2.5	4
105	Thienopyridine efficacy and cigarette smoking status. <i>American Heart Journal</i> , <b>2013</b> , 165, 693-703	4.9	9
104	Influence of platelet reactivity and inflammation on peri-procedural myonecrosis in East Asian patients undergoing elective percutaneous coronary intervention. <i>International Journal of Cardiology</i> , <b>2013</b> , 168, 427-35	3.2	3
103	The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 505-12	15.1	104
102	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , <b>2013</b> , 11, 447-62	2.5	16
101	PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection. <i>Future Cardiology</i> , <b>2013</b> , 9, 785-97	1.3	3
100	Usefulness of thrombelastography platelet mapping assay to measure the antiplatelet effect of P2Y(12) receptor inhibitors and high on-treatment platelet reactivity. <i>Platelets</i> , <b>2013</b> , 24, 166-9	3.6	12
99	Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. <i>Circulation: Cardiovascular Genetics</i> , <b>2013</b> , 6, 184-92		80
98	Platelet reactivity and thrombogenicity in postmenopausal women. <i>Menopause</i> , <b>2013</b> , 20, 57-63	2.5	16
97	Antiplatelet drug resistance and variability in response: the role of antiplatelet therapy monitoring. <i>Current Pharmaceutical Design</i> , <b>2013</b> , 19, 3795-815	3.3	15

96	Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 308, 1785-94	27.4	176
95	Translational platelet research in patients with coronary artery disease: what are the major knowledge gaps?. <i>Thrombosis and Haemostasis</i> , <b>2012</b> , 108, 12-20	7	6
94	Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation. <i>Thrombosis Research</i> , <b>2012</b> , 129, 1-2	8.2	26
93	Ticagrelor in the treatment of coronary artery disease patients. <i>Clinical Practice (London, England)</i> , <b>2012</b> , 9, 373-390	3	
92	Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. <i>American Heart Journal</i> , <b>2012</b> , 164, 35-42	4.9	60
91	Caution in interpreting the findings from small observational studies. <i>International Journal of Cardiology</i> , <b>2012</b> , 160, 71	3.2	
90	Pharmacokinetics and pharmacodynamics of ticagrelor in patients with stable coronary artery disease: results from the ONSET-OFFSET and RESPOND studies. <i>Clinical Pharmacokinetics</i> , <b>2012</b> , 51, 397-409	6.3	44
89	Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y <sub>12</sub> receptor inhibitors. <i>Expert Review of Cardiovascular Therapy</i> , <b>2012</b> , 10, 1011-22	2.5	
88	Does Gender have an Influence on Platelet Function and the Efficacy of Oral Antiplatelet Therapy?. <i>Interventional Cardiology Clinics</i> , <b>2012</b> , 1, 223-230	1.4	3
87	Clopidogrel efficacy and cigarette smoking status. <i>JAMA - Journal of the American Medical Association</i> , <b>2012</b> , 307, 2495-6	27.4	42
86	Importance of potent P2Y <sub>12</sub> receptor blockade in acute myocardial infarction: focus on prasugrel. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 1771-96	4	9
85	Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study. <i>European Heart Journal</i> , <b>2012</b> , 33, 2151-62	9.5	32
84	Pharmacodynamic effect of cilostazol plus standard clopidogrel versus double-dose clopidogrel in patients with type 2 diabetes undergoing percutaneous coronary intervention. <i>Diabetes Care</i> , <b>2012</b> , 35, 2194-7	14.6	8
83	Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TAPPER-CABG) study. <i>Circulation</i> , <b>2012</b> , 125, 2112-21	6	196
82	Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents. <i>Circulation</i> , <b>2012</b> , 125, 1276-87; discussion 1287	16.7	85
81	Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. <i>Cardiology Journal</i> , <b>2012</b> , 19, 230-42	1.4	8
80	Antiplatelet therapy beyond 2012: role of personalized medicine <b>2012</b> , 122, 298-305		2
79	Vorapaxar: a novel protease-activated receptor-1 inhibitor. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 1445-53	5.9	13

78 Resistance to Antiplatelet Therapy **2011**, 1

77	The effect of ticagrelor versus clopidogrel on high on-treatment platelet reactivity: combined analysis of the ONSET/OFFSET and RESPOND studies. <i>American Heart Journal</i> , <b>2011</b> , 162, 160-5	4.9	63
76	The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy. <i>American Heart Journal</i> , <b>2011</b> , 161, 598-604	4.9	68
75	Immunity to thrombotic events is achievable if we stop the guessing game: is this the major hidden message from GRAVITAS?. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 263-4	7	4
74	Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 265-71	7	26
73	Peri-operative platelet function testing: the potential for reducing ischaemic and bleeding risks. <i>Thrombosis and Haemostasis</i> , <b>2011</b> , 106, 248-52	7	23
72	The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity. <i>Journal of Cardiovascular Pharmacology</i> , <b>2011</b> , 57, 86-93	3.1	62
71	Role of ticagrelor in the treatment of coronary artery disease. <i>Clinical Investigation</i> , <b>2011</b> , 1, 429-437		
70	Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations. <i>JACC: Cardiovascular Interventions</i> , <b>2011</b> , 4, 365-80	5	43
69	Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 118-20	6	6
68	Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin. <i>Circulation: Cardiovascular Interventions</i> , <b>2011</b> , 4, 585-94	6	91
67	Assessment of oral antithrombotic therapy by platelet function testing. <i>Nature Reviews Cardiology</i> , <b>2011</b> , 8, 572-9	14.8	18
66	Current options in oral antiplatelet strategies during percutaneous coronary interventions. <i>Reviews in Cardiovascular Medicine</i> , <b>2011</b> , 12 Suppl 1, S4-13	3.9	1
65	Interaction between clopidogrel and proton-pump inhibitors and management strategies in patients with cardiovascular diseases. <i>Drug, Healthcare and Patient Safety</i> , <b>2010</b> , 2, 233-40	1.6	8
64	Combination antithrombotic therapies. <i>Circulation</i> , <b>2010</b> , 121, 569-83	16.7	96
63	Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. <i>Circulation</i> , <b>2010</b> , 121, 1188-99	16.7	372
62	First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. <i>Circulation: Cardiovascular Genetics</i> , <b>2010</b> , 3, 556-66		135
61	Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic Risk Progression (TRIP) study. <i>Platelets</i> , <b>2010</b> , 21, 360-7	3.6	62

60	Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 185-93	15.1	132
59	Genotyping: one piece of the puzzle to personalize antiplatelet therapy. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 112-6	15.1	71
58	Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 56, 919-33	15.1	913
57	Antiplatelet effects of aspirin with phytosterols: comparison with non-enteric coated aspirin alone. <i>Thrombosis Research</i> , <b>2010</b> , 126, 384-5	8.2	4
56	Hypothesis formulation from subgroup analyses: nonadherence or nonsteroidal anti-inflammatory drug use explains the lack of clinical benefit of aspirin on first myocardial infarction attributed to "aspirin resistance". <i>American Heart Journal</i> , <b>2010</b> , 159, 744-8	4.9	28
55	Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. <i>American Heart Journal</i> , <b>2010</b> , 160, 346-54	4.9	123
54	Ticagrelor for the treatment of arterial thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2251-9	4	21
53	Controversies in oral antiplatelet therapy in patients undergoing aortocoronary bypass surgery. <i>Annals of Thoracic Surgery</i> , <b>2010</b> , 90, 1040-51	2.7	22
52	The link between heightened thrombogenicity and inflammation: pre-procedure characterization of the patient at high risk for recurrent events after stenting. <i>Platelets</i> , <b>2009</b> , 20, 97-104	3.6	36
51	Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. <i>JAMA - Journal of the American Medical Association</i> , <b>2009</b> , 302, 849-57	27.4	1070
50	Aspirin resistance. <i>Progress in Cardiovascular Diseases</i> , <b>2009</b> , 52, 141-52	8.5	64
49	Effect of long-term clopidogrel treatment on platelet function and inflammation in patients undergoing coronary arterial stenting. <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1546-50	3	41
48	Prevalence of aspirin and clopidogrel resistance among patients with and without drug-eluting stent thrombosis. <i>American Journal of Cardiology</i> , <b>2009</b> , 104, 525-30	3	46
47	Selecting optimal antiplatelet therapy based on platelet function monitoring in patients with coronary artery disease. <i>Current Treatment Options in Cardiovascular Medicine</i> , <b>2009</b> , 11, 22-32	2.1	11
46	Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. <i>Circulation</i> , <b>2009</b> , 120, 2577-85	16.7	866
45	Bivalirudin and clopidogrel with and without eptifibatide for elective stenting: effects on platelet function, thrombelastographic indexes, and their relation to periprocedural infarction results of the CLEAR PLATELETS-2 (Clopidogrel with Eptifibatide to Arrest the Reactivity of Platelets) study. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 648-57	15.1	55
44	Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2009</b> , 5, 989-1004	5.5	62
43	Antiplatelet resistance--fact or myth?. <i>The American Heart Hospital Journal</i> , <b>2009</b> , 7, 50-7		1

42	Response variability and the role of platelet function testing. <i>Journal of Invasive Cardiology</i> , <b>2009</b> , 21, 172-8	0.7	9
41	The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 531-3	15.1	187
40	Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. <i>American Heart Journal</i> , <b>2008</b> , 155, 56-61	4.9	35
39	Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target. <i>Platelets</i> , <b>2008</b> , 19, 595-604	3.6	89
38	Diagnostics for aspirin resistance. <i>Molecular Diagnosis and Therapy</i> , <b>2008</b> , 12, 55-6	4.5	
37	Race and sex differences in thrombogenicity: risk of ischemic events following coronary stenting. <i>Blood Coagulation and Fibrinolysis</i> , <b>2008</b> , 19, 268-75	1	38
36	Dark chocolate effect on platelet activity, C-reactive protein and lipid profile: a pilot study. <i>Southern Medical Journal</i> , <b>2008</b> , 101, 1203-8	0.6	56
35	Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 657-66	15.1	328
34	AZD6140. <i>Expert Opinion on Investigational Drugs</i> , <b>2007</b> , 16, 225-9	5.9	48
33	The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. <i>Diabetes</i> , <b>2007</b> , 56, 3014-9	0.9	174
32	Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. <i>Platelets</i> , <b>2007</b> , 18, 414-23	3.6	42
31	Inflammatory changes during the common cold are associated with platelet activation and increased reactivity of platelets to agonists. <i>Blood Coagulation and Fibrinolysis</i> , <b>2007</b> , 18, 713-8	1	29
30	Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting. <i>Thrombosis Research</i> , <b>2007</b> , 119, 563-70	8.2	40
29	Clopidogrel resistance?. <i>Thrombosis Research</i> , <b>2007</b> , 120, 311-21	8.2	137
28	Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients. <i>Thrombosis Research</i> , <b>2007</b> , 121, 107-15	8.2	47
27	Clopidogrel resistance: implications for coronary stenting. <i>Current Pharmaceutical Design</i> , <b>2006</b> , 12, 1261-9	3.9	18
26	Drug insight: Clopidogrel nonresponsiveness. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2006</b> , 3, 387-95		89
25	Prasugrel. <i>Expert Opinion on Investigational Drugs</i> , <b>2006</b> , 15, 1627-33	5.9	18

24	Effect of clopidogrel with and without eptifibatide on tumor necrosis factor-alpha and C-reactive protein release after elective stenting: results from the CLEAR PLATELETS 1b study. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 2186-91	15.1	71
23	Aspirin and clopidogrel resistance: consideration and management. <i>Journal of Interventional Cardiology</i> , <b>2006</b> , 19, 439-48	1.8	43
22	Clinical applications of antiplatelet therapy. <i>Reviews in Cardiovascular Medicine</i> , <b>2006</b> , 7, 130-46; quiz 148-9	3.9	2
21	The difference between clopidogrel responsiveness and posttreatment platelet reactivity. <i>Thrombosis Research</i> , <b>2005</b> , 115, 89-94	8.2	123
20	The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 1392-6	15.1	317
19	Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1705-9	15.1	258
18	Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1820-6	15.1	561
17	Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1827-32	15.1	461
16	The platelet-related effects of tenecteplase versus alteplase versus reteplase. <i>Blood Coagulation and Fibrinolysis</i> , <b>2005</b> , 16, 1-7	1	17
15	Resistance to antiplatelet drugs: current status and future research. <i>Expert Opinion on Pharmacotherapy</i> , <b>2005</b> , 6, 2027-45	4	54
14	Clopidogrel loading with eptifibatide to arrest the reactivity of platelets: results of the Clopidogrel Loading With Eptifibatide to Arrest the Reactivity of Platelets (CLEAR PLATELETS) study. <i>Circulation</i> , <b>2005</b> , 111, 1153-9	16.7	312
13	Platelet activation in myocardial ischemic syndromes. <i>Expert Review of Cardiovascular Therapy</i> , <b>2004</b> , 2, 535-45	2.5	69
12	Wound fluid inhibits wound fibroblast nitric oxide synthesis. <i>Journal of Surgical Research</i> , <b>2004</b> , 122, 43-8.5	8.5	6
11	Modulation of growth factor and cytokine expression by nitric oxide during rat colon anastomotic healing. <i>Journal of Gastrointestinal Surgery</i> , <b>2003</b> , 7, 393-9	3.3	9
10	Differential cytokine expression in skin graft healing in inducible nitric oxide synthase knockout mice. <i>Plastic and Reconstructive Surgery</i> , <b>2001</b> , 108, 1251-9	2.7	9
9	A novel method of studying wound healing. <i>Journal of Surgical Research</i> , <b>2001</b> , 98, 16-20	2.5	9
8	Nitric oxide in the healing wound: a time-course study. <i>Journal of Surgical Research</i> , <b>2001</b> , 101, 104-8	2.5	95
7	Inhibition of tumor necrosis factor-alpha attenuates wound breaking strength in rats. <i>Wound Repair and Regeneration</i> , <b>2000</b> , 8, 547-53	3.6	56

6	Sepsis impairs anastomotic collagen gene expression and synthesis: a possible role for nitric oxide. <i>Journal of Surgical Research</i> , <b>1997</b> , 69, 81-6	2.5	29
5	Nitric oxide metabolism in wounds. <i>Journal of Surgical Research</i> , <b>1997</b> , 71, 25-31	2.5	94
4	Stimulation of fibroblast proliferation and matrix contraction by wound fluid. <i>International Journal of Biochemistry and Cell Biology</i> , <b>1997</b> , 29, 231-9	5.6	32
3	Intra-abdominal sepsis impairs colonic reparative collagen synthesis. <i>American Journal of Surgery</i> , <b>1996</b> , 171, 102-7; discussion 107-8	2.7	84
2	Nitric oxide regulates wound healing. <i>Journal of Surgical Research</i> , <b>1996</b> , 63, 237-40	2.5	225
1	Thienopyridine Response Variability and Resistance77-93		